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Editorial
(Ultra-)low dosing of rituximab in rheumatoid
arthritis: chances and challenges
This editorial refers to ‘Low-dose rituximab protocol
in rheumatoid arthritis—outcome and economic im-
pact’, by Parvathypriya Chandramohan et al.
In a recent paper in this Journal, Chandramohan et al.
[1] showed, in an uncontrolled study, that a single infu-
sion of 500 mg rituximab (RTX) can be effective in a
large proportion of RA patients. At face value, it seems
rather peculiar that 14 years after registration of RTX for
RA in the USA (1 March 2006) the evidence for optimal
RTX dosing still keeps evolving, and this deserves a
closer look.
Rituximab, a biological DMARD targeting CD20þ
B cells, effectively decreases disease activity in patients
with RA and can prevent disease progression. The cur-
rent recommendation of the US Food and Drug
Administration and European Medicines Agency consists
of two doses of 1000 mg RTX (2 weeks apart), every
6 months. RTX had originally been developed as a treat-
ment for non-Hodgkin’s lymphoma, and the dosing for
patients with RA was based directly on dosing used in
lymphoma.
Interestingly, no classical phase I/II dose finding stud-
ies have been done in RA. This is likely to be attribut-
able to choices by the originator pharmaceutical
company, Roche, presumably based on the apparent
safety of the higher 41000 mg dosing and a relative
lack of interest in developing this drug in RA. There was
also, potentially, a lack of incentive to study lower dos-
ing of RTX in RA, because the price for non-Hodgkin’s
lymphoma had already been established, and different
cross-disease pricing is cumbersome, if not unfeasible.
Thus, a (much) lower RTX dose for RA would be unat-
tractive commercially.
To our knowledge (after searching patent documenta-
tion, published trials and trial registries and contacting
Roche) the above factors resulted in a lack of formal
clinical testing of doses lower than 11000/2 500 mg,
with the exception of a very small study combining
500 mg/m2 RTX (i.e. 850 mg with an average body sur-
face area) with CYC in four patients [2]. This knowledge
gap has been identified by several researchers, and
since the early 2010s a number of studies have been
done in a kind of race to the bottom regarding optimal
RTX dosing in RA.
First, it was shown successfully that the effects of
RTX are comparable when using 11000 mg/
2500 mg compared with the authorized 2 1000 mg in
three randomized controlled trials [3]. But things would
not end here. In three case reports and a small
observational open label study, even (much) lower doses
of RTX (50–200 mg) led to complete peripheral B cell de-
pletion and often apparently adequate disease control
[4].
Based on these serendipitous findings, the REDO
(https://www.thelancet.com/journals/lanrhe/article/PIIS26
65-9913(19)30066-9/fulltext) study was designed, show-
ing that in RA patients doing well on RTX 11000 mg/
2500 mg, a retreatment strategy with 1500 or
1200 mg was as effective, although the study failed
formally to meet the primary per protocol non-inferiority
outcome [4]. Interestingly, the 200 mg seemed to work
at least as well (pharmacokinetically, pharmacodynami-
cally and clinically) as 500 mg, and this again suggests
that even lower dosing might be possible.
Now comes the study by Chandramohan et al. [1],
showing the apparent effectiveness of 1500 mg RTX
in RA patients commencing RTX treatment. This study
has some important limitations, including absence of a
control group and the open label design, with sugges-
tion of some regression to the mean in disease activity
measurements, in addition to intensive co-treatment
with conventional synthetic DMARDs. However, in our
view the data still strongly suggest that 1 500 mg is an
effective treatment in RA, and this notion fits in well with
the aforementioned established evidence base.
Some questions remain. How low can or should we
go? Why even bother? Regarding the first question, no
clinical dose–response curve for RTX in RA has ever
been published that clearly shows a relationship pla-
teauing off at a certain dose. Indeed, complete periph-
eral B cell depletion has been demonstrated after
dosages even as low as 1 or 3 mg. Therefore, the jury is
still out on this, and it might well be that even (much)
lower dosages than 200 mg, albeit maybe combined
with a treatment interval shorter than 6 months, are
enough to treat RA. But why pursue this? After all, RTX
already seems very safe in the higher dosages, and
costs seem manageable, especially when using stan-
dard low dosing of 11000 mg/2500 mg and biosimi-
lars where available. We think that the main drivers for
researching the lowest effective RTX dose in RA are
threefold: safety, cost and ease of use.
Regarding safety, although RTX has a low infection
risk associated with it [5], the REDO study showed that
infections were 50% lower for the 500 and 200 mg com-
pared with 1000 mg dosages, even in this relatively
small study. Also, RTX seems to be a risk factor for spe-
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progressive multifocal leukoencephalopathy) [6] and,
more recently, potentially coronavirus disease 2019
(COVID-19) [7]. These risks have, however, been esti-
mated in real-world data, using full- or half-dosed RTX,
thus the use of lower dosages might well ameliorate
these already small risks further. Also of interest in these
times of COVID-19 are data showing that humoral vac-
cine response is decreased after RTX. Although there is
not yet supporting evidence for this, conceptually, the
use of very low-dosed RTX might well ameliorate this
disadvantageous effect.
Concerning cost, it should be noted that the view of
non-high-income countries on what costs are accept-
able differs vastly from that of high-income countries, as
mentioned explicitly by Chandramohan et al. [1]. Even in
The Netherlands, lowering the dose per administration
from 1 1000 mg per 6 months to 1 500 mg would
halve the net yearly RTX cost to e2300 ($2600); consid-
erably lower, but still six times more costly than oral
MTX. Also, infusion facilities add costs to the total cost
of RTX treatment, and this observation also leads to the
third reason to go as low as we can: ease of use.
Finally, lower doses can greatly improve the ease of use
by opening the possibility of s.c. administration. An s.c.
administration of RTX is being used in haematology, but
includes a rather large volume of >11 ml. Keeping a bio-
availability of 70% in mind, 200 mg i.v. dosing might be
substituted elegantly for 300 mg s.c. RTX dosing (2 ml),
negating the need for infusion facilities and reducing some
patient burden associated with i.v. administration [8].
In conclusion, we think that the study by
Chandramohan et al. [1] highlights the road we have
travelled regarding RTX dosing in RA, but also illumi-
nates the road ahead with lower doses of RTX, poten-
tially leading to the safest and most cost-effective
modern treatment option in RA.
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